OWPC · One World Products, Inc. · Financials
$0.00
+0.00 (+0.00%)
At close · Nov 12
Return incl. dividend (before tax)
Going-concern doubt
— flagged Jan 2, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of September 30, 2025, our balance of cash on hand was $168,620, and we had negative working capital of $3,953,402 and an accumulated deficit of $26,120,538. We are too early in our development stage to project future revenue levels and may not be able to generate sufficient funds to sustain our operations for the next twelve months. Accordingly, we will need to raise additional cash to fund our operations. These factors raise substantial doubt about the Company's ability to continue as a going concern. In the event sales do not materialize at the expected rates, management will seek additional financing and will attempt to conserve cash by further reducing expenses. There can be no assurance that we will be successful in achieving these objectives; therefore, without sufficient financing it would be unlikely for the Company to continue as a going concern.”View the 10-Q filed Jan 2, 2026
Market Cap
$36,033
Shares
120.11M
Volume · Nov 12
139.29K
Avg daily vol (3M)
226.43K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$4863
-35.9%
FY2024
Net Income
-$3.94M
+0.5%
FY2024
Gross Margin
80.51%
+2261.7pp
FY2024
Operating Margin
-38494.63%
-11075.1pp
FY2024
Diluted EPS
-$0.04
+20%
FY2024
Operating Cash Flow
-$1.12M
+6.1%
FY2024
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $53.43K | $4863 | $7589 | $125.66K | $38.26K | $59.57K | — | — | — | — | — | |
| $2063 | $948 | $173.12K | $300.76K | $19.74K | $104.73K | — | — | — | — | — | |
| $51.37K | $3915 | -$165.53K | -$175.1K | $18.52K | -$45.16K | — | — | — | — | — | |
| — | 80.51% | -2181.22% | -139.34% | 48.4% | -75.81% | — | — | — | — | — | |
| $303.61K | $653.98K | $1.29M | $1.59M | $2.29M | $3.96M | $2.23M | $7441 | $18.15K | $36.66K | $22.46K | |
| — | $0 | $34.27K | $42.29K | $40.32K | $33.61K | $19.67K | — | — | — | — | |
| $1.08M | $1.88M | $1.92M | $2.06M | $3.25M | $7.87M | $5.82M | $26.96K | $56.88K | — | $26.5K | |
| — | — | — | — | $102.99K | — | — | — | — | — | — | |
| -$1.02M | -$1.87M | -$2.08M | -$2.24M | -$3.23M | -$7.92M | -$5.82M | -$26.96K | -$56.88K | -$36.66K | -$22.46K | |
| — | -38494.63% | -27419.57% | -1779.48% | -8444.76% | -13291.65% | — | — | — | — | — | |
| — | -$1.87M | -$2.05M | -$2.19M | -$3.19M | -$7.88M | -$5.8M | — | — | — | — | |
| $142.14K | $471.01K | $308.74K | $956.86K | $511.13K | $47.59K | $382.58K | — | — | — | — | |
| — | — | $7 | $38 | $2358 | — | — | — | — | — | — | |
| $5.13M | -$2.06M | -$1.87M | -$823.34K | -$553.26K | -$47.59K | -$386.67K | — | — | $14.77K | — | |
| — | -$245.27K | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | -$56.88K | -$21.89K | — | |
| $4.11M | -$3.94M | -$3.95M | -$3.06M | -$3.78M | -$7.97M | -$6.21M | -$26.96K | -$56.88K | -$21.89K | -$22.46K | |
| — | -80917.38% | -52092.78% | -2434.69% | -9890.66% | -13371.54% | — | — | — | — | — | |
| $4.05M | -$4.04M | -$3.92M | -$3.08M | -$3.86M | -$9.54M | -$6.22M | — | — | — | — | |
| $4.11M | -$3.98M | -$3.86M | -$3.05M | -$3.8M | -$8M | -$6.22M | — | -$56.88K | -$21.89K | -$22.46K | |
| USD/shares | $0.04 | -$0.04 | -$0.05 | -$0.05 | -$0.06 | — | — | — | — | — | — |
| USD/shares | $0.04 | -$0.04 | -$0.05 | -$0.05 | — | — | — | — | — | — | — |
| shares | — | 106.97M | 73.33M | 66.19M | 60.6M | 48.83M | 41.09M | 1.32M | 1.32M | 5.29M | 5.29M |
| shares | — | 106.97M | 73.33M | 66.19M | 60.6M | 48.83M | 41.09M | 1.32M | 1.32M | 5.29M | 5.29M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Read debt and covenant terms in your AI or your code through MCP and the API →Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Notes payable, including current maturities | 2024-06-30 | USD 2,236,828 | 10-Q filed 2024-08-21 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Drug Manufacturers - Specialty & Generic median 1.94×
EV/EBIT
—
Drug Manufacturers - Specialty & Generic median 17.56×
P/E (TTM)
—
Drug Manufacturers - Specialty & Generic median 14.18×
Price/Sales (TTM)
—
Drug Manufacturers - Specialty & Generic median 1.76×
Price/Book
—
Drug Manufacturers - Specialty & Generic median 1.59×